Omnicef (Cefdinir)
Dosages
Omnicef 300 mg
| Quantity | Price per tablet | Total price | |
|---|---|---|---|
| 30 | $4.47 | $134.00 | |
| 60 | $3.67 | $220.00 | |
| 90 | $3.39 | $305.00 | |
| 120 | $3.26 | $391.00 | |
| 180 | $3.12 | $561.00 |
Payment & Shipping
Your order is carefully packed and ships within 24 hours. Here is what a typical package looks like.
Sized like a regular personal letter (9.4x4.3x0.3 inches), with no indication of what is inside.
| Shipping Method | Estimated delivery |
|---|---|
| Express Free for orders over $300.00 | Estimated delivery to the U.S.: 4-7 days |
| Standard Free for orders over $200.00 | Estimated delivery to the U.S.: 14-21 days |
Discount Coupons
- Independence Day - July 4, 2026 10% JULY410
- Labor Day - September 7, 2026 7% LABOR07
- Thanksgiving - November 26, 2026 9% THANKS09
Brand Names
| Country | Brand Names |
|---|---|
 India | Cednir Cefdair Cefdiel Kefnir Sefdin |
 Japan | Cefzon |
 Malaysia | Cefdiel |
| Manufacturer | Brand Names |
|---|---|
| Ranbaxy Laboratories Ltd. | Adcef Cefdiel |
| Torrent Pharmaceuticals Limited | Adcef Cefdiel |
Description
Cefdinir (brand: Omnicef) is a third-generation oral cephalosporin antibiotic available as capsules and as an oral suspension. It is used to treat certain mild to moderate bacterial infections caused by susceptible organisms. Use cefdinir only as prescribed—antibiotics do not treat viral infections (such as colds or flu).
What it is used for
In U.S. labeling, cefdinir is indicated for select infections when caused by susceptible bacteria, including community-acquired pneumonia, pharyngitis/tonsillitis (strep throat), acute maxillary sinusitis, acute bacterial exacerbations of chronic bronchitis, uncomplicated skin infections, and (in pediatric patients) acute bacterial otitis media (ear infections).
Ear infections
Cefdinir may be prescribed for acute bacterial otitis media in pediatric patients when caused by susceptible strains of Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains).
Strep throat
For pharyngitis/tonsillitis (“strep throat”), cefdinir is indicated when caused by susceptible Streptococcus pyogenes. Cefdinir can eradicate S. pyogenes from the throat, but it has not been studied for prevention of rheumatic fever after strep pharyngitis/tonsillitis (only intramuscular penicillin has been shown to prevent rheumatic fever).
Pneumonia
For community-acquired pneumonia, cefdinir is indicated for infections due to susceptible strains of Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Moraxella catarrhalis (including β-lactamase producing strains), and Streptococcus pneumoniae (penicillin-susceptible strains only).
UTI
Cefdinir is not FDA-approved for urinary tract infections. Some clinicians may use it off-label in specific situations based on local resistance patterns and urine culture/susceptibility results. Do not use cefdinir for a UTI unless your prescriber specifically recommends it.
Side effects
Common side effects reported with cefdinir include diarrhea, nausea, headache, rash, and vaginal yeast infection (in some women). Seek urgent medical help for signs of a severe allergic reaction (hives, swelling of the face/lips/tongue, trouble breathing). Contact a clinician promptly for severe or persistent diarrhea, especially if it is watery or bloody.
Comparison: cefdinir vs amoxicillin vs Augmentin
| Feature | Cefdinir | Amoxicillin | Augmentin (amoxicillin/clavulanate) |
|---|---|---|---|
| Class / route | 3rd-gen cephalosporin; oral capsule or oral suspension | Penicillin-class; oral (various forms) | Penicillin-class + β-lactamase inhibitor; oral (various forms) |
| Ear infections (AOM) | Indicated in pediatric AOM due to susceptible H. influenzae, S. pneumoniae (penicillin-susceptible strains only), M. catarrhalis | Indicated for ENT infections due to susceptible β-lactamase–negative isolates | Indicated for AOM caused by β-lactamase–producing H. influenzae and M. catarrhalis |
| Strep throat | Indicated for pharyngitis/tonsillitis due to susceptible S. pyogenes; not studied for rheumatic fever prevention | Commonly used for susceptible streptococcal ENT infections (product-specific labeling varies) | May be used when broader coverage is needed; still penicillin-class |
| Pneumonia | Indicated for community-acquired pneumonia due to susceptible organisms | Labeling includes lower respiratory tract infections due to susceptible β-lactamase–negative isolates | Labeling includes LRTI due to β-lactamase–producing H. influenzae and M. catarrhalis |
| Penicillin allergy | Cross-reactivity between penicillins and 3rd-generation cephalosporins is generally low, but patients with a history of immediate or severe reactions (e.g., anaphylaxis) should discuss options carefully with a clinician. | A true penicillin allergy is a major concern—do not take unless your clinician confirms it is safe for you. | Same penicillin-class concern as amoxicillin; do not take unless your clinician confirms it is safe for you. |
| Common side effects (general) | Diarrhea, nausea, headache, rash; yeast infection in some women | GI upset, rash (varies by product and patient) | GI upset (often more diarrhea), rash (varies by product and patient) |
Storage
Capsules and dry powder should be stored at 77°F (25°C); excursions permitted to 59–86°F (15–30°C). After mixing, the oral suspension is stored at controlled room temperature 68–77°F (20–25°C). Shake well before each dose and discard any unused suspension after 10 days. Refrigeration is not required; avoid freezing.
Cefdinir (Omnicef) is an oral antibiotic used for certain respiratory infections (including community-acquired pneumonia), strep throat caused by susceptible bacteria, and (in children) some ear infections. It is not FDA-approved for UTIs, and antibiotic choice depends on the infection site, susceptibility, and your allergy history.
